These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226 [TBL] [Abstract][Full Text] [Related]
45. Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies. Hardenberg MC; Sinnige T; Casford S; Dada ST; Poudel C; Robinson EA; Fuxreiter M; Kaminksi CF; Kaminski Schierle GS; Nollen EAA; Dobson CM; Vendruscolo M J Mol Cell Biol; 2021 Aug; 13(4):282-294. PubMed ID: 33386842 [TBL] [Abstract][Full Text] [Related]
46. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. Henderson MX; Trojanowski JQ; Lee VM Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426 [TBL] [Abstract][Full Text] [Related]
47. Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease. Matsui H; Ito S; Matsui H; Ito J; Gabdulkhaev R; Hirose M; Yamanaka T; Koyama A; Kato T; Tanaka M; Uemura N; Matsui N; Hirokawa S; Yoshihama M; Shimozawa A; Kubo SI; Iwasaki K; Hasegawa M; Takahashi R; Hirai K; Kakita A; Onodera O Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2214652120. PubMed ID: 37252975 [TBL] [Abstract][Full Text] [Related]
48. Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease. Kardani J; Sethi R; Roy I Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1454-1463. PubMed ID: 28167231 [TBL] [Abstract][Full Text] [Related]
49. The effect of mutant GBA1 on accumulation and aggregation of α-synuclein. Maor G; Rapaport D; Horowitz M Hum Mol Genet; 2019 Jun; 28(11):1768-1781. PubMed ID: 30615125 [TBL] [Abstract][Full Text] [Related]
50. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease. Pavlou MAS; Pinho R; Paiva I; Outeiro TF Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855 [TBL] [Abstract][Full Text] [Related]
51. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. Engelender S Autophagy; 2008 Apr; 4(3):372-4. PubMed ID: 18216494 [TBL] [Abstract][Full Text] [Related]
52. Parkinson disease: α-synuclein mutational screening and new clinical insight into the p.E46K mutation. Pimentel MM; Rodrigues FC; Leite MA; Campos Júnior M; Rosso AL; Nicaretta DH; Pereira JS; Silva DJ; Della Coletta MV; Vasconcellos LF; Abreu GM; Dos Santos JM; Santos-Rebouças CB Parkinsonism Relat Disord; 2015 Jun; 21(6):586-9. PubMed ID: 25817515 [TBL] [Abstract][Full Text] [Related]
53. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743 [TBL] [Abstract][Full Text] [Related]
54. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Dehay B; Bourdenx M; Gorry P; Przedborski S; Vila M; Hunot S; Singleton A; Olanow CW; Merchant KM; Bezard E; Petsko GA; Meissner WG Lancet Neurol; 2015 Aug; 14(8):855-866. PubMed ID: 26050140 [TBL] [Abstract][Full Text] [Related]
56. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease. Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353 [TBL] [Abstract][Full Text] [Related]